Large-scale rare variant burden testing in Parkinson's disease
Brain · 02.11.2023 · 146 (11) · 4622-4632
DOI: 10.1093/brain/awad214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 22.06.2023. Verfasst von Mary B Makarious und 36 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20814, USA. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Medical Research Council, Intramural NIH HHS.
Abstract (Originalsprache)
Parkinson’s disease has a large heritable component and genome-wide association studies have identified over 90 variants with disease-associated common variants, providing deeper insights into the disease biology. However, there have not been large-scale rare variant analyses for Parkinson’s disease. To address this gap, we investigated the rare genetic component of Parkinson’s disease at minor allele frequencies <1%, using whole genome and whole exome sequencing data from 7184 Parkinson’s disease cases, 6701 proxy cases and 51 650 healthy controls from the Accelerating Medicines Partnership Parkinson's disease (AMP-PD) initiative, the National Institutes of Health, the UK Biobank and Genentech. We performed burden tests meta-analyses on small indels and single nucleotide protein-altering variants, prioritized based on their predicted functional impact. Our work identified several genes reaching exome-wide significance. Two of these genes, GBA1 and LRRK2, have variants that have been previously implicated as risk factors for Parkinson’s disease, with some variants in LRRK2 resulting in monogenic forms of the disease. We identify potential novel risk associations for variants in B3GNT3, AUNIP, ADH5, TUBA1B, OR1G1, CAPN10 and TREML1 but were unable to replicate the observed associations across independent datasets. Of these, B3GNT3 and TREML1 could provide new evidence for the role of neuroinflammation in Parkinson’s disease. To date, this is the largest analysis of rare genetic variants in Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20814, USA.
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
- UCL Movement Disorders Centre, University College London, London WC1N 3BG, UK.
- Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20814, USA.
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08854, USA.
- Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA.
ORCID-Profile: Mary B Makarious, Kimberley J Billingsley, Dan Vitale, Ali Torkamani, Mina Ryten, Sonja W Scholz, Toshiko Tanaka, Luigi Ferrucci, Geidy E Serrano, Raquel Real, Huw R Morris, Cornelis Blauwendraat
Förderung
- NIA NIH HHS
- Medical Research Council
- Intramural NIH HHS
- NCATS NIH HHS
- NINDS NIH HHS
- Intramural Research Program
- National Institutes of Health
- National Institute on Aging
Zitieren
APA
Makarious, M. B., Lake, J., Pitz, V., Ye Fu, A., Guidubaldi, J. L., Solsberg, C. W., Bandres-Ciga, S., Leonard, H. L., Kim, J. J., Billingsley, K. J., Grenn, F. P., Jerez, P. A., Alvarado, C. X., Iwaki, H., Ta, M., Vitale, D., Hernandez, D., Torkamani, A., Ryten, M., …, & Blauwendraat, C. (2023). Large-scale rare variant burden testing in Parkinson's disease. Brain, 146(11), 4622-4632. https://doi.org/10.1093/brain/awad214
Vancouver
Makarious MB, Lake J, Pitz V, Ye Fu A, Guidubaldi JL, Solsberg CW, et al. Large-scale rare variant burden testing in Parkinson's disease. Brain. 2023;146(11):4622-4632. doi:10.1093/brain/awad214
BibTeX
@article{Makarious2023,
author = {Makarious, Mary B and Lake, Julie and Pitz, Vanessa and Ye Fu, Allen and Guidubaldi, Joseph L and Solsberg, Caroline Warly and Bandres-Ciga, Sara and Leonard, Hampton L and Kim, Jonggeol Jeffrey and Billingsley, Kimberley J and Grenn, Francis P and Jerez, Pilar Alvarez and Alvarado, Chelsea X and Iwaki, Hirotaka and Ta, Michael and Vitale, Dan and Hernandez, Dena and Torkamani, Ali and Ryten, Mina and Hardy, John and UK Brain Expression Consortium (UKBEC),, UK Brain Expression Consortium (UKBEC), and Scholz, Sonja W and Traynor, Bryan J and Dalgard, Clifton L and Ehrlich, Debra J and Tanaka, Toshiko and Ferrucci, Luigi and Beach, Thomas G and Serrano, Geidy E and Real, Raquel and Morris, Huw R and Ding, Jinhui and Gibbs, J Raphael and Singleton, Andrew B and Nalls, Mike A and Bhangale, Tushar and Blauwendraat, Cornelis},
title = {Large-scale rare variant burden testing in Parkinson's disease},
journal = {Brain},
year = {2023},
volume = {146},
number = {11},
pages = {4622--4632},
doi = {10.1093/brain/awad214}
}
EUVIMED